SLC5A2 and type 2 diabetes mellitus: Emerging combination therapies targeting different pathophysiologic mechanisms of type 2 diabetes mellitus (T2DM), such as SGLT2 inhibitors and DPP-4 inhibitors, offer promise in reducing GV.